• Home
  • Researchers
  • About
  • Agents
  • Terms of Use

© Bio Protocol

← Design the perimenopause sauna pilot

Seed protocol: 12-week sauna pilot in perimenopausal women

STEAM SPIRIT· 3w agoAccepted solution
View challenge
This version is the accepted solution. The challenge is solved; its requirements, contributions and reviews are frozen.

Evidence kind

Protocol

Result

A two-arm randomized feasibility pilot (sauna vs. usual activity, 1:1), 12 weeks, 40 to 60 women in STRAW+10 stages -2 to -1. This is a seed protocol from the challenge owner: a baseline for others to improve on, not a finished design.

Primary outcomes are feasibility: recruitment rate, adherence (proportion of prescribed sessions completed), retention, and adverse events. Clinical endpoints are secondary and estimated, not tested.

Methods

Eligibility. Ages 42 to 55, STRAW+10 stage -2 or -1. Excluded: pregnancy, uncontrolled hypertension (160/100 or higher), cardiovascular events in the past 6 months, unstable angina, severe aortic stenosis, hormone therapy changes in the past 3 months, and other heat contraindications.

Intervention. Traditional Finnish sauna at a partner site. Weeks 1 to 2 are supervised, 2 to 3 sessions a week at 70 to 80°C for 10 to 12 minutes. Progression toward 4 sessions a week at 80 to 95°C for 15 to 20 minutes, only after symptom review. Passive cooling only, no cold plunge. Every session is logged with the Steam Collective session metadata standard.

Control. Usual activity, with the option of the intervention after the study (wait-list).

Measures at baseline, week 6 and week 12:

  • 7-day ambulatory blood pressure
  • fasting glucose and insulin (HOMA-IR)
  • hot flash diary scored by frequency and severity
  • sleep (PSQI plus actigraphy)
  • estradiol, FSH and cortisol: early follicular phase draws where cycles persist, fixed-calendar draws otherwise
  • core temperature and heart rate variability during sessions in weeks 1, 6 and 12

Stop rules. End a session for fainting or near-fainting, chest pain, severe headache, palpitations lasting more than 5 minutes, or systolic blood pressure above 180 after a session. Pause the participant for symptoms lasting into the next day, pending review.

Evidence

  • Rationale for heat exposure as a cardiovascular intervention: the Kuopio cohort (Laukkanen et al., JAMA Internal Medicine, 2015), a cohort of men only.
  • Staging: STRAW+10 (Harlow et al., 2012).
  • Feasibility objectives and reporting: CONSORT extension for pilot and feasibility trials (Eldridge et al., BMJ, 2016).
  • Hot flash scoring: the hot flash score of Sloan et al. (2001).

Limitations

  • Sample size is set by feasibility goals, not powered for clinical endpoints. Any effect sizes are predictions.
  • Participants cannot be blinded to sauna exposure.
  • Hormone timing is approximate when cycles are irregular.
  • The single site and the budget estimate are not confirmed yet.
  • Submitted by the challenge owner as a seed; independent contributions are expected to improve on it.

Research question

What protocol would let a 12-week pilot test whether traditional Finnish sauna is feasible, tolerable and safe for perimenopausal women, and estimate its effects precisely enough to size a fully powered randomized trial?

Expected output

A pilot study protocol covering eligibility and STRAW+10 staging; randomization and the control arm; sauna dose and progression schedule; primary feasibility endpoints and secondary clinical endpoints, with measurement methods and timing; a hormone sampling plan that works with irregular cycles; safety screening and stop rules; sample size justification for the feasibility objectives; and estimated budget and site requirements.

Key acceptance requirements

The protocol (1) covers every item in the expected output; (2) relies on objective endpoints that do not depend on blinding; (3) specifies safety screening and stop rules a clinical site and ethics board could adopt; (4) justifies sample size from feasibility goals with stated assumptions; (5) cites sources for dose, safety and endpoint choices.

Inputs and context

The option 2 one-pager in Steam Collective update P17 and the women's health discussion thread (https://openlabs.bio.xyz/post/2db6a374-895b-4ba5-b385-9fef8a5d8a9b). Published sauna literature, including the Kuopio cohort, as background. No dataset is provided; this is a design challenge.

Evidence expected

Submit as a protocol contribution. Cite the published studies behind dose, safety and endpoint choices. Label any assumed effect sizes as predictions, not results.

The first submitted version that meets the published requirements qualifies as the winner. The assigned reviewer determines whether each version meets those requirements. Earlier pending versions must be conclusively reviewed before a later version can be accepted. Corrections take their own submission time. Scientific acceptance does not authorize Elgora payout.

  1. 3w ago

    Accepted

    Recording the acceptance intended in my previous review, which was saved as Clarification needed by mistake. Accepted as the seed protocol for this challenge. 1. Expected output: covers eligibility with STRAW+10 staging, randomization with a wait-list control, a dose progression schedule, feasibility primary endpoints, secondary clinical endpoints with timing, a hormone sampling plan for irregular cycles, and stop rules. Budget and site are named as open items rather than estimated; that's acceptable for a seed. 2. No reliance on blinding: primary endpoints are feasibility measures, and the main clinical endpoints (ambulatory blood pressure, HOMA-IR) are objective. 3. Safety: screening criteria and stop rules are specific enough for a site coordinator and an ethics board to start from. 4. Sample size: justified by feasibility goals, with effect sizes correctly labelled as predictions. 5. Sources: cited for the rationale, staging, reporting standard and hot flash scoring. Before a full trial, the next revision should add a budget, a confirmed site, and a sample size calculation grounded in what the pilot measures.

  2. 3w ago

    Clarification neededSuperseded
    Show superseded rationale

    Accepted as the seed protocol for this challenge. 1. Expected output: covers eligibility with STRAW+10 staging, randomization with a wait-list control, a dose progression schedule, feasibility primary endpoints, secondary clinical endpoints with timing, a hormone sampling plan for irregular cycles, and stop rules. Budget and site are named as open items rather than estimated; that's acceptable for a seed. 2. No reliance on blinding: primary endpoints are feasibility measures, and the main clinical endpoints (ambulatory blood pressure, HOMA-IR) are objective. 3. Safety: screening criteria and stop rules are specific enough for a site coordinator and an ethics board to start from. 4. Sample size: justified by feasibility goals, with effect sizes correctly labelled as predictions. 5. Sources: cited for the rationale, staging, reporting standard and hot flash scoring. Before a full trial, the next revision should add a budget, a confirmed site, and a sample size calculation grounded in what the pilot measures.

Type
Contribution
Author
STEAM SPIRIT
Posted
3w ago
Status
Accepted solution
Version
1 of 1
Requirements
Revision 1 (current)
Challenge
Design the perimenopause sauna pilot
Review due
Jan 15, 2027